BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 27389021)

  • 1. High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients.
    D'Agostino G; Franzese C; De Rose F; Franceschini D; Comito T; Villa E; Alongi F; Liardo R; Tomatis S; Navarria P; Mancosu P; Reggiori G; Cozzi L; Scorsetti M
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e173-e178. PubMed ID: 27389021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study.
    D'Agostino GR; Mancosu P; Di Brina L; Franzese C; Pasini L; Iftode C; Comito T; De Rose F; Guazzoni GF; Scorsetti M
    Am J Clin Oncol; 2020 Sep; 43(9):628-635. PubMed ID: 32889832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.
    Boyer MJ; Papagikos MA; Kiteley R; Vujaskovic Z; Wu J; Lee WR
    Radiat Oncol; 2017 Jan; 12(1):14. PubMed ID: 28086825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life.
    Scorsetti M; Alongi F; Clerici E; Comito T; Fogliata A; Iftode C; Mancosu P; Navarria P; Reggiori G; Tomatis S; Villa E; Cozzi L
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1795-800. PubMed ID: 24906878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.
    D'Agostino GR; Badalamenti M; Stefanini S; Baldaccini D; Franzese C; Faro LL; Di Cristina L; Vernier V; Reggiori G; Scorsetti M
    Prostate; 2024 Mar; 84(4):368-375. PubMed ID: 38112222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study.
    Alongi F; Cozzi L; Arcangeli S; Iftode C; Comito T; Villa E; Lobefalo F; Navarria P; Reggiori G; Mancosu P; Clerici E; Fogliata A; Tomatis S; Taverna G; Graziotti P; Scorsetti M
    Radiat Oncol; 2013 Jul; 8():171. PubMed ID: 23835141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy.
    D'Agostino GR; Di Brina L; Mancosu P; Franzese C; Iftode C; Franceschini D; Clerici E; Tozzi A; Navarria P; Scorsetti M
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):614-621. PubMed ID: 30825495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
    Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.
    Hannan R; Tumati V; Xie XJ; Cho LC; Kavanagh BD; Brindle J; Raben D; Nanda A; Cooley S; Kim DWN; Pistenmaa D; Lotan Y; Timmerman R
    Eur J Cancer; 2016 May; 59():142-151. PubMed ID: 27035363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I/II Study of Stereotactic Hypofractionated Once-weekly Radiation Therapy (SHORT) for Prostate Cancer.
    Mallick I; Arunsingh M; Chakraborty S; Arun B; Prasath S; Roy P; Dabkara D; Achari R; Chatterjee S; Gupta S
    Clin Oncol (R Coll Radiol); 2020 Feb; 32(2):e39-e45. PubMed ID: 31551125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
    Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
    Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
    Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial.
    McBride SM; Wong DS; Dombrowski JJ; Harkins B; Tapella P; Hanscom HN; Collins SP; Kaplan ID
    Cancer; 2012 Aug; 118(15):3681-90. PubMed ID: 22170628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute.
    Prendergast BM; Dobelbower MC; Bonner JA; Popple RA; Baden CJ; Minnich DJ; Cerfolio RJ; Spencer SA; Fiveash JB
    Radiat Oncol; 2013 Nov; 8():273. PubMed ID: 24256563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.